TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22993101
Drug: lopinavir/ritonavir monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: lopinavir/ritonavir monotherapy (mLPV/r)
Study: 11718517
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg melatonin
Study: 8524494
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (500 mg intravenously after haemodialysis, 1-3 times a week)
Study: 1914619
Drug: Terfenadine, 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine, 120 mg
Study: 25327884
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (CIT) 900 mg kg(‐1)
Study: 17314114
Drug: 1.0 kcal/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 kcal/ml nocturnal enteral feed (NEF)
Study: 17314114
Drug: 1.5 kcal/ml
Normalized name: lactose-reduced food 0.05 gram-1.5 kcal/mL ORAL LIQUID (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 kcal/ml nocturnal enteral feed (NEF)
Study: 9489937
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg oral caffeine
Study: 9489937
Drug: 4 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg/kg oral caffeine
Study: 9489937
Drug: 0 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/kg oral caffeine (control group)
Study: 7827353
Drug: Diabetic patients
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diabetic patients before treatment
Study: 2901252
Drug: Neuroleptic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuroleptic treatment (medication continued)
Study: 2901252
Drug: Drug-withdrawn patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-withdrawn patients (some clinically relapsed)
Study: 28794291
Drug: Allopurinol, 100
Normalized name: Allopurinol, 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol, 100 mg daily for 12 months
Study: 27004309
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BTxA) injection (20 IU, 0.2 ml)
Study: 27004309
Drug: 0.9% NaCl
Normalized name: Trace Metals Additive in 0.9% NaCl
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution injection (0.2 ml)
Study: 23094638
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg + Amlodipine 10 mg
Study: 21193281
Drug: Experiential‐existential therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experiential‐existential therapy groups
Study: 17182297
Drug: Alendronate 10
Normalized name: ALENDRONATE 10MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate 10 mg/day (ALN)
Study: 17314736
Drug: Raloxifene 60
Normalized name: raloxifene 60 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 60 mg/day (RLX)
Study: 11505331
Drug: STW‐5 (herbal
Approvals — FDA: no, EMA: no, PMDA: no
Description: STW‐5 (herbal preparation containing bitter candy tuft and other extracts)
Study: 11505331
Drug: STW‐5‐S (modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: STW‐5‐S (modified preparation without bitter candy tuft)
Study: 2676440
Drug: Ketanserin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketanserin (20-40 mg twice a day)
Study: 30799474
Drug: K-etchant GEL
Normalized name: Effer-K
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-etchant GEL (KE)
Study: 20491814
Drug: Group E
Normalized name: Prostaglandin group E
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group E (control, no bone augmentation)
Study: 17489080
Drug: Circumferential sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circumferential sequential gradient compression (CSG)
Study: 17489080
Drug: Posterior sequential
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Posterior sequential rapid gradient inflation device (PSR)
Study: 12394199
Drug: Salt tablets
Normalized name: bile salts Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salt tablets (approximately 700 mg/h of sodium)
Study: 31524133
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation (BA) therapy, up to 15 sessions over 4 months.
Study: 31524133
Drug: Behavioural Activation
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioural Activation (BA) therapy.
Study: 24215565
Drug: Artemisinin-naphthoquine (ANQ)
Normalized name: naphthoquine
DrugBank: Naphthoquine (DB16249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemisinin-naphthoquine (ANQ) - total target dose of 24.5 mg/kg (naphthoquine 7 mg/kg and artemisinin 17.5 mg/kg), once a day for three days
Study: 24215565
Drug: Chloroquine-primaquine (CQ-PQ)
Normalized name: chloroquine / primaquine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine-primaquine (CQ-PQ) - total CQ dose of 24 mg base/kg, once a day for three days plus PQ dose of 0.45 mg base/kg/day, once a day for eight days
Study: 1449620
Drug: Simple chemotherapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple chemotherapy regimens
Study: 1449620
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy regimens
Study: 31960409
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion thresholds (105 g/l, maintaining 110-125 g/l)
Study: 31960409
Drug: Restrictive transfusion
Normalized name: Pinus spp. wood destructive distillate
DrugBank: Pine tar (DB15840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive transfusion thresholds (80 g/l, to maintain haemoglobin 85-100 g/l)
Study: 27455842
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg peri-articular TXA
Study: 27455842
Drug: 750 mg
Normalized name: bran 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg IV TXA
Study: 24325778
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Simvastatin and Bezafibrate
Study: 15628812
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine (Lantus)
Study: 18715206
Drug: Insulin glulisine
Normalized name: Insulin Glulisine
DrugBank: Insulin glulisine (DB01309)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin glulisine (Apidra)
Study: 15741724
Drug: 20% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% (w/v) sucrose plus 70 microg Fe/ml
Study: 15741724
Drug: 20% (w/v)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20% (w/v) sucrose plus 18 microg Fe/ml
Study: 10800070
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell dose greater than 5 x 106/kg
Study: 10800070
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell dose higher than 5 x 106/kg
Study: 10800070
Drug: CD34+ cell
Normalized name: CD34+ Cells
DrugBank: Autologous peripheral blood-derived CD34+ cells (DB16367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD34+ cell dose lower than 5 x 106/kg
Study: 8471413
Drug: Ranitidine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (150 mg)
Study: 19855988
Drug: Fluoroscopy-guided thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopy-guided thermal ablation therapy
Study: 8712826
Drug: MMC (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: MMC (4 mg, twice a week, total 1 mg/kg) + OK-432 (or PSK)
Study: 8712826
Drug: MMC +
Normalized name: MMC
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: MMC + OK-432 + HCFU (600 mg, per day)
Study: 4035328
Drug: sn‐polyenylphosphatidylcholin (PPC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sn‐polyenylphosphatidylcholin (PPC) 450 mg b.i.d. (three times daily)
Study: 24285336
Drug: Supervised walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised walking (60 min three times weekly for 3 months)
Study: 17241101
Drug: Inhaled β2-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled β2-agonists (formoterol, salbutamol, salmeterol, terbutaline)
Study: 12153065
Drug: Self-administered history
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered history questionnaire
Study: 1979796
Drug: Cetirizine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine (5 to 20 mg once daily)
Study: 1979796
Drug: Hydroxyzine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (25 to 75 mg/day in divided doses)
Study: 31326304
Drug: Daily oral
Normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily oral l-arginine plus tadalafil
Study: 31326304
Drug: Single drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drugs (either l-arginine or tadalafil)
Study: 23790420
Drug: Night extension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Night extension orthosis plus hand therapy
Study: 23790420
Drug: Hand therapy
Normalized name: Octinoxate 3.00 mL in 75 mL / Avobenzone 1.5 mL in 75 mL TOPICAL CREAM [Botanics Daily Hand Therapy Sunscreen SPF 10]
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hand therapy alone
Study: 18922988
Drug: Hemoglobin target
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin target of 13.5 to 14.5 g/dl
Study: 18922988
Drug: Hemoglobin target
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin target of 9.5 to 11.5 g/dl
Study: 11137633
Drug: Newer generation
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newer generation dentine‐bonding agents
Study: 7869013
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 to 8 mg) monotherapy
Study: 7869013
Drug: Perindopril (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4 to 8 mg) in combination with hydrochlorothiazide (50 mg/day)
Study: 2832030
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH, Enoxaparine) 60 mg daily
Study: 2832030
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH, Enoxaparine) 40 mg daily
Study: 2832030
Drug: Low molecular
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low molecular weight heparin (LMWH, Enoxaparine) 20 mg daily
Study: 2832030
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UH) 5000 units daily
Study: 31980285
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg BID)
Study: 31960705
Drug: Accelerated Resolution
Normalized name: Revolution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Resolution Therapy (ART)
Study: 14703598
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CRP > 10 pg/mL plus IL‐6 > 18 pg/mL at 0-hour
Study: 10716520
Drug: Beta-blockers (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blockers (n = 33)
Study: 10716520
Drug: No beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: No beta-blockers (n = 32)
Study: 1641252
Drug: Treatment (expulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (expulsion of Trichuris trichiura)
Study: 6829944
Drug: Atropine 0.02
Normalized name: ATROPINE 0.025/DIFENOXIN 1MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.02 mg/kg intramuscularly before induction
Study: 31860965
Drug: N2O titration
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O titration (30% to ideal sedation concentration)
Study: 31860965
Drug: N2O titration
Normalized name: N2O
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N2O titration
Study: 22951193
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of methylprednisolonacetate
Study: 16421163
Drug: Epoetin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin (in vitro treatment of PBMs)
Study: 12671377
Drug: Thrombin solution
Normalized name: thrombin
DrugBank: Thrombin (DB11300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombin solution (control)
Study: 1882909
Drug: Sucralfate (1-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1-g tablet twice a day for 4 months)
Study: 6133059
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g glucose plus 70 mmol NaHCO3
Study: 16449709
Drug: Benzodiazepine tapering-off
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzodiazepine tapering-off programme without psychotherapy
Study: 9419047
Drug: Placebo (from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (from ALS CNTF Treatment Study)
Study: 3525270
Drug: Sucrose meal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose meal (50 g) with Acarbose 100 mg
Study: 3525270
Drug: Sucrose meal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose meal (50 g) without Acarbose
Study: 3525270
Drug: Sucrose meal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose meal (75 g) with Acarbose 100 mg
Study: 3525270
Drug: Sucrose meal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose meal (75 g) without Acarbose
Study: 3525270
Drug: Sucrose meal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose meal (100 g) with Acarbose 100 mg
Study: 3525270
Drug: Sucrose meal
Normalized name: Sucrose
DrugBank: Sucrose (DB02772)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sucrose meal (100 g) without Acarbose
Study: 3525270
Drug: Acarbose (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (0 mg, 50 mg, 100 mg, 200 mg) with fixed sucrose load (75 g)
Study: 24613816
Drug: HFX (hyperfractionation),
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFX (hyperfractionation), 81.6 Gy/68 twice‐daily fractions/7 weeks
Study: 24613816
Drug: SFX (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFX (standard fractionation), 70 Gy/35 daily fractions/7 weeks
Study: 24613816
Drug: 7-week treatments
Normalized name: Weeks and Leo Complete Lice Treatment KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7-week treatments
Study: 24151792
Drug: Training preschool
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training preschool teachers using a manual covering health education, health promotion, incorporation of oral‐health‐friendly activities into the preschool curriculum, and hands‐on experience of oral examination.
Study: 14597032
Drug: No IOP-lowering
Approvals — FDA: no, EMA: no, PMDA: no
Description: No IOP-lowering treatment
Study: 1442914
Drug: Deep injection
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep injection technique with plain lidocaine
Study: 3956889
Drug: Radiotelemetry capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotelemetry capsule measurements
Study: 3956889
Drug: Antisecretory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antisecretory agent
Study: 30244873
Drug: PCV15 (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV15 (both formulations)
Study: 11071086
Drug: Antibiotic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic therapy (duration: 72-96 hours)
Study: 31758589
Drug: Alkali-modified implants
Normalized name: alkali blite pollen extract
DrugBank: Suaeda moquinii pollen (DB10953)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkali-modified implants
Study: 31758589
Drug: Sandblasted implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sandblasted implants
Study: 28399035
Drug: Interferon alpha‐2b
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon alpha‐2b (1,000,000 units/cc) eye drops
Study: 18594971
Drug: Amoxicillin, omeprazole,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, omeprazole, furazolidone, bismuth (Group B)
Study: 18594971
Drug: Amoxicillin, clarithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin, clarithromycin, omeprazole (Group C)
Study: 16439432
Drug: Acetazolamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (4 mg kg(‐1)) + Antioxidants (1 g ascorbic acid i.v. and 200 mg alpha‐tocopherol p.o.)
Study: 16439432
Drug: Acetazolamide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetazolamide (4 mg kg(‐1)) + Placebo
Study: 15238591
Drug: Enoxaparin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (1 mg/kg every 12 hours)
Study: 12890401
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (adjusted doses)
Study: 11208394
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment for 8 weeks, diet restriction, and regular exercise
Study: 11208394
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 8 weeks, no behavioral treatment
Study: 11208394
Drug: Cimetidine treatment
Normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cimetidine treatment for 8 weeks followed by 42 months of intervention
Study: 11208394
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 8 weeks followed by 42 months of non-intervention
Study: 9235656
Drug: Local injections
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local injections of glucocorticosteroids
Study: 9235656
Drug: Glucocorticosteroids injections
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticosteroids injections
Study: 1389662
Drug: iohexol (intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol (intraarterial injection)
Study: 1389662
Drug: ioxaglate (intraarterial
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate (intraarterial injection)
Study: 1389662
Drug: ioxaglate (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: ioxaglate (intravenous injection)
Study: 1389662
Drug: iohexol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: iohexol (intravenous injection)
Study: 28482864
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (normal daily exercise routine)
Study: 21415660
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg etoricoxib (nonsteroidal anti-inflammatory)
Study: 21415660
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg dexamethasone (corticosteroid anti-inflammatory)
Study: 18317068
Drug: Cetuximab 250
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250 mg/m(2) weekly IV and gefitinib 250 mg/d PO
Study: 12808176
Drug: Enoxaparin (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (mean dose of 0.68 mg/kg)
Study: 12808176
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (mean bolus of 42.1 IU/kg and continuous infusion of 57.8 IU/kg)
Study: 8590960
Drug: G‐DAMME 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐DAMME 250 micrograms IV as a bolus at time 0'
Study: 8590960
Drug: G‐DAMME preceded
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐DAMME preceded by hGH
Study: 1706666
Drug: low-dose epirubicin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: low-dose epirubicin
Study: 7042201
Drug: Unable to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unable to tolerate antacids
Study: 7042201
Drug: Medication (antacids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication (antacids or cimetidine)
Study: 30834689
Drug: Topical formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical formulation with di- and tripeptides
Study: 30834689
Drug: Oral supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplementation based on hydrolyzed collagen
Study: 30059671
Drug: GS-0976 20
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-0976 20 mg
Study: 30059671
Drug: GS-0976 5
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-0976 5 mg
Study: 11981362
Drug: Once-daily SQV-SGC/RTV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily SQV-SGC/RTV (1600/100 mg)
Study: 2043500
Drug: DHAP (dexamethasone/high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHAP (dexamethasone/high‐dose cytarabine/cisplatin) for two courses at 3‐ to 4‐week intervals
Study: 24418368
Drug: On-demand therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand therapy
Study: 28697991
Drug: Carbamazepine 400
Normalized name: carbamazepine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbamazepine 400 mg before surgery
Study: 28697991
Drug: Addicted patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Addicted patients (no treatment)
Study: 10950231
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg oral insulin daily
Study: 10950231
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg oral insulin daily
Study: 9210279
Drug: Feminist-cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feminist-cognitive-behavioral treatment
Study: 9210279
Drug: Process-psychodynamic treatment
Normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Process-psychodynamic treatment